Portal de Periódicos da CAPES

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

2015; American Society for Microbiology; Volume: 59; Issue: 10 Linguagem: Inglês

10.1128/aac.01165-15

1098-6596

Romney M. Humphries, Shangxin Yang, Peera Hemarajata, Kevin W. Ward, Janet A. Hindler, Shelley A. Miller, Aric L. Gregson,

Tuberculosis Research and Epidemiology

Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.